All In Biotech

Drug Trial Radar · NCT04390737

Evaluate the Safety and Clinical Activity of HH2853

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

254

Planned (sponsor's estimate)

Start

Sep 8, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Haihe Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

Conditions

  • FL Lymphoma
  • Epithelioid Sarcoma
  • Peripheral T Cell Lymphoma
  • Advanced Solid Tumor

Interventions

  • HH2853 TabletsDrug

    Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated Dose (MTD)Time frame: 28-day treatment cycles
  2. Recommended phase II dose (RP2D)Time frame: 28-day treatment cycles
  3. Adverse events assessed according to NCI-CTCAE V5.0Time frame: 28-day treatment cycles
  4. Dose limiting toxicities (DLT)Time frame: 28-day treatment cycles
  5. Objective response rate (ORR)Time frame: 28-day treatment cycles

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona · Completed

  • Mayo Clinic

    Jacksonville, Florida · Completed

  • Mayo Clinic

    Rochester, Minnesota · Completed

  • NEXT Oncology

    San Antonio, Texas · Completed

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • Sun Yat-Sen University Cancer Hospital

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Jishuitan Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-Sen University Cancer Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Affiliated Drum Tower Hospital, Medical School of Nanjing University

    Nanjing, Jiangsu, China · Recruiting

  • Liaoning Cancer Hospital&Institute

    Shenyang, Liaoning, China · Recruiting

  • Shengjing Hospital Of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Linyi Tumor Hospital

    Linyi, Shandong, China · Recruiting

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.